We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Inverness Acquires Abbotts' Rapid Diagnostics

By HospiMedica staff writers
Posted on 13 Jun 2005
Print article
In a transaction that will enhance the company's product line, Inverness Medical Innovations (Waltham, MA, USA) will acquire the Determine/DainaScreen assets of the rapid diagnostics business of Abbott Laboratories (Abbott Park, IL, USA) for U.S.$56.5 million.

The assets include diagnostics for hepatitis, HIV, and syphilis, as well as manufacturing equipment and certain licensed intellectual property related to the products. In 2004, the business represented by Determine/DainaScreen generated revenues of about $23 million.

Abbott will continue to distribute the Determine products, which are marketed outside the United States, for up to three months and will receive a sales commission on net sales. Under a long term-supply arrangement, Inverness will sell products to Abbott that will allow Abbott to continue to distribute the Determine HIV ½ rapid test at no profit to Abbott through the Abbott Access to HIV Care programs in 69 countries, including all of Africa and the least-developed countries. Abbott also will continue to donate Determine HIV tests purchased from Inverness to programs that address mother-to-child transmission of HIV in the same countries.

"This acquisition allows Inverness to enhance its professional diagnostics product line with the addition of the premiere rapid HIV test worldwide,” remarked Ron Zwanziger, chairman, president, and CEO, Inverness Medical.



Related Links:
Inverness
Abbott
New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
Automated Blood Typing System
IH-500 NEXT
New
Automatic Biochemistry Analyzer
Audmax 180 Evolution
New
Centrifuge
Centrifuge 5430/ 5430 R

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.